Medication

FILE - This June 15, 2018, file photo shows pharmaceuticals in North Andover, Mass. A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington. (AP Photo/Elise Amendola, File)
December 19, 2019 - 4:43 pm
A revamped North American trade deal nearing passage in Congress gives both the White House and Democrats a chance to claim victory and offers farmers and businesses clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact leaves at least one...
Read More
FILE - This Thursday, May 3, 2018 file photo shows bottles of gabapentin at a pharmacy in San Francisco. On Thursday, Dec. 18, 2019, U.S. health regulators are warning that popular nervous system medications known generically as gabapentin and pregabalin can cause dangerous breathing problems when combined with opioids and certain other drugs. (AP Photo/Jeff Chiu)
December 19, 2019 - 4:33 pm
WASHINGTON (AP) — U.S. health regulators are warning that popular nervous system medications can cause dangerous breathing problems when combined with opioids and certain other drugs. The Food and Drug Administration said Thursday it would add new warnings to packaging for Neurontin, Lyrica and...
Read More
December 19, 2019 - 3:44 pm
WASHINGTON (AP) — U.S. health regulators are warning that popular nervous system medications can cause dangerous breathing problems when combined with opioids and certain other drugs. The Food and Drug Administration said Thursday it would add new warnings to packaging for Neurontin, Lyrica and...
Read More
FILE - This June 15, 2018, file photo shows pharmaceuticals in North Andover, Mass. A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington. (AP Photo/Elise Amendola, File)
December 19, 2019 - 11:07 am
A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But...
Read More
This undated photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On Friday, Dec. 13, 2019, U.S. regulators approved expanded use of the medication for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. (Amarin via AP)
December 13, 2019 - 5:56 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood...
Read More
This undated photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On Friday, Dec. 13, 2019, U.S. regulators approved expanded use of the medication for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. (Amarin via AP)
December 13, 2019 - 5:53 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood...
Read More
December 13, 2019 - 5:35 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood...
Read More
This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys 53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months earlier. (Sarepta Therapeutics via AP)
December 13, 2019 - 4:19 pm
WASHINGTON (AP) — U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago. The ruling marks the second time the Food and Drug Administration has granted preliminary...
Read More
In this Thursday, Oct. 31, 2019, photo, a recovering tramadol user waits for her medication at a de-addiction center in Kapurthala, in the northern Indian state of Punjab. The pills were everywhere, as legitimate medication sold in pharmacies, but also illicit counterfeits hawked by itinerant peddlers and street vendors. India has twice the global average of illicit opiate consumption. Researchers estimate about 4 million Indians use heroin or other opioids, and a quarter of them live in the Punjab, India's agricultural heartland bordering Pakistan. (AP Photo/Channi Anand)
December 13, 2019 - 3:23 pm
KAPURTHALA, India (AP) — Reports rolled in with escalating urgency — pills seized by the truckload, pills swallowed by schoolchildren, pills in the pockets of dead terrorists. These pills, the world has been told, are safer than the OxyContins, the Vicodins, the fentanyls that have wreaked so much...
Read More
This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys 53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months earlier. (Sarepta Therapeutics via AP)
December 13, 2019 - 2:28 pm
WASHINGTON (AP) — U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago. The ruling marks the second time the Food and Drug Administration has granted preliminary...
Read More

Pages